Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and outlicensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang’s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.
Mustang believes that harnessing the body’s own immune system to treat cancer is the next generation of cancer care that may prove curative across tumor types that have proved resilient to standard pharmacological and biological treatments. CAR T uses the patient’s own T-cells to engage and destroy specific tumors. The process involves selecting specific T-cell subtypes, genetically engineering them to express chimeric antigen T-cell receptors and placing them back in the patient where they recognize and destroy cancer cells.
Mustang’s exclusive license and sponsored research agreement at the COH encompasses specific chimeric T-cell constructions and enabling process technologies including linker technology improvements. This agreement covers the discovery, manufacturing and clinical development of novel Chimeric Antigen Receptor engineered T-cells (CAR T) along with specified rights to any and all inventions.
Two of the CAR Ts from our collaboration with the COH are already in Phase 1 clinical development. The first is a proprietary engineered Chimeric Antigen Receptor T-cells targeting interleukin 13 Receptor α2 which is overexpressed on the surface of glioblastoma (GBM) cells.
The second is a proprietary CAR T targeting of CD123, which is overexpressed on the surface of Acute Myeloid Leukemia (AML) cells.
Mustang also has a sponsored preclinical research agreement in place with COH to develop additional CAR T cell products.